DNA vaccination against bcr-abl-positive cells in mice

International Journal of Oncology

Volumn 35, Issue 4, 2009, Pages 941-951

  Lucansky, Vincent ^a   Sobotkova, Eva ^a   Tachezy, Ruth ^a   Duskova, Martina ^a   Vonka, Vladimir ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Bcr abl transformed mouse cells; CML; DNA vaccines

Indexed keywords

BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; DNA FRAGMENT; DNA VACCINE; PLASMID DNA; PROTEIN P25;

ACUTE LEUKEMIA; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER PREVENTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA IMMUNIZATION; FUSION GENE; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; LIVER PARENCHYMA; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN;

ANIMALS; CANCER VACCINES; EPITOPE MAPPING; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; IMMUNIZATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; TIME FACTORS; TRANSFECTION; VACCINES, DNA;

EID: 70449434669     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000408     Document Type: Article

References (33)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R and Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med 341: 164-172, 1999.
2. Mauro MJ and Druker BJ: Chronic myelogenous leukemia. Curr Opin Oncol 13: 3-7, 2001.
3. Barnes DJ and Melo JV: Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 5: 2862-2866, 2006.
4. Shah NP: Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program pp183-187, 2005.
5. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A and Griffin JD: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7: 345-356, 2007. (Pubitemid 46652483)
6. Goldman JM and Druker BJ: Chronic myeloid leukemia: current treatment options. Blood 98: 2039-2042, 2001.
7. Bocchia M, Korontsvit T, Xu Q, et al: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87: 3587-3592, 1999. (Pubitemid 26129585)
8. He L, Feng H, Raymond A, et al: Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother 50: 31-40, 2001. (Pubitemid 32250044)
9. Leeksma OC, Kessler JH, Huijbers IJ, Ten Bosch GJ and Melief CJ: BCR-ABL directed immunotherapy: a virtual reality? Leuk Lymphoma 38: 175-181, 2000.
10. Li Z, Qiao Y, Liu B, et al: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 11: 4460-4468, 2005. (Pubitemid 40825636)
11. Norbury LC, Clark RE and Christmas SE: b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 109: 616-621, 2000.
12. Osman Y, Takahashi M, Zheng Z, et al: Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13: 166-174, 1999. (Pubitemid 29092648)
13. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95: 1781-1787, 2000. (Pubitemid 30120843)
14. Pinilla-Ibarz J, Cathcart K and Scheinberg DA: CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 14: 111-120, 2000. (Pubitemid 30616184)
15. Reichardt VL and Brossart P: Current status of vaccination therapy for leukemias. Curr Hematol Rep 4: 73-76, 2005.
16. Ren R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172-183, 2005. (Pubitemid 40314949)
17. Sun JY, Krouse RS, Forman SJ, et al: Immunogenicity of a p210 (BCR-ABL) vision domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vaccine in vitro. Cancer Res 62: 3175-3183, 2002.
18. Takahashi T, Tanaka Y, Nieda M, et al: Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 27: 795-802, 2003. (Pubitemid 36683326)
19. Deeb D, Gao X, Jiang H, Divine G, Dulchavsky SA and Gautam SC: Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse. J Exp Ther Oncol 5: 183-193, 2006. (Pubitemid 43843829)
20. Kislin KL, Marron MT, Li G, Graner MW and Katsanis E: Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumour activity against a murine BCR-ABL positive leukemia. FASEB J 21: 2173-2184, 2007. (Pubitemid 47026452)
21. Zeng Y, Feng H, Graner MW and Katsanis E: Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101: 4485-4491, 2003. (Pubitemid 36857818)
22. Zeng Y, Graner MW, Feng H, Li G and Katsanis E: Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer 110: 251-259, 2004. (Pubitemid 38580399)
23. Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM and Clark RE: Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 90: 1315-1323, 2005. (Pubitemid 41503646)
24. Guilhot F, Roy L, Martineua G, Guilhot J and Millot F: Immuno-therapy in chronic myelogenous leukemia. Clin Lymphoma Myeloma 2: 64-70, 2007.
25. Grünebach F, Mirakaj V, Mirakaj V, Müller MR, Brümmendorf T and Brossart P: BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 66: 5892-5900, 2006. (Pubitemid 43927144)
26. Jelinek F, Sobotkova E and Vonka V: Characteristics of two mouse bcr-abl-transformed cell lines. II. Pathological lesions induced in mice. Folia Biol (Praha) 51: 93-102, 2005.
27. Smahel M, Pokorna D, Mackova J and Vlasak J: Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J Gene Med 6: 1092-1101, 2004. (Pubitemid 40232987)
28. Smahel M, Sima P, Ludvikova V and Vonka V: Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238, 2001. (Pubitemid 32881139)
29. Daley G Q and Baltimore D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr-abl protein. Proc Natl Acad Sci USA 85: 9312-9316, 1988.
30. McLaughlin J, Chianese E and Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84: 6558-6562, 1987.
31. Sobotkova E, Ludvikova V, Petrackova M, et al: Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells. Folia Biol (Praha) 51: 12-18, 2005. Erratum in: 158, 2005.
32. Sobotkova E, Duskova M, Tachezy R, Petrackova M and Vonka V: Combined chemo- and immunotherapy of tumours induced in mice by bcr-abl-transformed cells. Oncol Rep 21: 793-799, 2009.
33. Ludvikova V, Hamsikova E, Sobotkova E, Lucansky V, Smahel M and Vonka V: Use of polyclonal rabbit antibodies for detection of the bcr-abl fusion zone in cells transfected with experimental bcr-abl DNA vaccines. Int J Oncol 27: 265-274, 2005.